Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis

References

• De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441.
   PubMed Web of Science ®Google Scholar
• Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood. 2003;102:43–52.
   PubMed Web of Science ®Google Scholar
• Mailankody S, Pfeiffer RM, Kristinsson SY, et al. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood. 2011;118:4086–4092.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry. Blood. 2009;113(18):4179–4187.
   PubMed Web of Science ®Google Scholar
• Alibhai SM, Leach M, Minden MD, et al. Outcomes and quality of care in acute myeloid leukemia over 40 years. Cancer. 2009;115(13):2903–2911.
   PubMed Web of Science ®Google Scholar
• Lerch E, Espeli V, Zucca E, et al. Prognosis of acute myeloid leukemia in the general population: data from southern Switzerland. Tumori. 2009;95(3):303–310.
   PubMed Web of Science ®Google Scholar
• Robak T, Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther. 2009;31(Pt 2):2349–2370.
   PubMed Web of Science ®Google Scholar
• Tettamanti S, Magnani CF, Biondi A, et al. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors. Immunol Lett. 2013;155(1–2):43–46.
   PubMed Web of Science ®Google Scholar
• Feldman EJ, Gergis U. Management of refractory acute myeloid leukemia: re-induction therapy or straight to transplantation? Curr Hematol Malig Rep. 2012;7(1):74–77.
   PubMed Web of Science ®Google Scholar
• Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042–2054.
   PubMed Web of Science ®Google Scholar
• Milosevic JD, Kralovics R. Genetic, epigenetic alterations of myeloproliferative disorders. Int J Hematol. 2013;97:183–197.
   PubMed Web of Science ®Google Scholar
• Schoofs T, Berdel WE, Muller-Tidow C. Origins of aberrant DNA methylation in acute myeloid leukemia. Leukemia. 2014;28:1–14.
   PubMed Web of Science ®Google Scholar
• Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol. 2005;2(Suppl 1):S4–S11.
   PubMedGoogle Scholar
• Shimizu R, Muto T, Aoyama K, et al. Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia. Leuk Res. 2016;50:85–94.
   PubMed Web of Science ®Google Scholar
• Atallah E, Kantarjian H, Garcia-Manero G. The role of decitabine in the treatment of myelodysplastic syndromes. Expert Opin Pharmacother. 2007;8(1):65–73.
   PubMed Web of Science ®Google Scholar
• Gurion R, Vidal L, Gafter-Gvili A, et al. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome–a systematic review and meta-analysis. Haematologica. 2010;95(2):303–310.
   PubMed Web of Science ®Google Scholar
• Hurd PJ, Whitmarsh AJ, Baldwin GS, et al. Mechanism-based inhibition of C5-cytosine DNA methyltransferases by 2-H pyrimidinone. J Mol Biol. 1999;286:389–401.
   PubMed Web of Science ®Google Scholar
• Marks PW. Decitabine for acute myeloid leukemia. Expert Rev Anticancer Ther. 2012;12(3):299–305.
   PubMed Web of Science ®Google Scholar
• Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol. 2007;25(25):3884–3891.
   PubMed Web of Science ®Google Scholar
• Blum W, Schwind S, Tarighat SS, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood. 2012;119(25):6025–6031.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108(10):3271–3279.
   PubMed Web of Science ®Google Scholar
• Halpern AB, Othus M, Huebner EM, et al. Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study. Leukemia. 2017;31(12):2560–2567.
   PubMed Web of Science ®Google Scholar
• Hao J, Wang L, Wang Y, et al. Comparative analysis of decitabine combined with DAG regimen and other regimens in treatment of refractory/relapsed acute myeloid leukemia. Zhonghua Xue Ye Xue Za Zhi. 2014;35(6):481–485. Chinese.
   PubMedGoogle Scholar
• Jiang X, Wang Z, Ding B, et al. The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients. Oncotarget. 2015;6(32):33612–33622.
   PubMedGoogle Scholar
• Kirschbaum M, Gojo I, Goldberg SL, et al. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. Br J Haematol. 2014;167(2):185–193.
   PubMed Web of Science ®Google Scholar
• Liesveld JL, O'Dwyer K, Walker A, et al. A phase I study of decitabine and rapamycin in relapsed/refractory AML. Leuk Res. 2013;37(12):1622–1627.
   PubMed Web of Science ®Google Scholar
• Mims AS, Mishra A, Orwick S, et al. A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485. Haematologica. 2018;103(6):982–987.
   PubMed Web of Science ®Google Scholar
• Muppidi MR, Portwood S, Griffiths EA, et al. Decitabine and sorafenib therapy in FLT-3 ITD-mutant acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015;15 (Suppl):S73–S79.
   PubMed Web of Science ®Google Scholar
• Ritchie EK, Feldman EJ, Christos PJ, et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk Lymphoma. 2013;54(9):2003–2007.
   PubMed Web of Science ®Google Scholar
• Schroeder T, Rautenberg C, Krüger W, et al. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative transplant study Group. Ann Hematol. 2018;97(2):335–342.
   PubMed Web of Science ®Google Scholar
• Sun Y, Xu Y, Wu D, et al. Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen. Zhonghua Xue Ye Xue Za Zhi. 2015;36(12):1025–1030. Chinese.
   PubMedGoogle Scholar
• Welch JS, Niu H, Uy GL, et al. A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. Am J Hematol. 2014;89(8):E103–E108.
   PubMed Web of Science ®Google Scholar
• Willemze R, Archimbaud E, Muus P. Preliminary results with 5-aza-2'-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC leukemia Cooperative Group. Leukemia. 1993;7(Suppl 1):49–50.
   PubMed Web of Science ®Google Scholar
• Willemze R, Suciu S, Archimbaud E, et al. A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC leukemia Cooperative Group phase II study (06893). Leukemia. 1997;11(Suppl 1):S24–S27.
   PubMed Web of Science ®Google Scholar
• Williams CB, Kambhampati S, Fiskus W, et al. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia. Pharmacotherapy. 2013;33(12):1341–1352.
   PubMed Web of Science ®Google Scholar
• Zhang LY, Yuan YQ, Zhou DM, et al. Impact of global and gene-specific DNA methylation in de novo or relapsed acute myeloid leukemia patients treated with decitabine. Asian Pac J Cancer Prev. 2016;17(1):431–437.
   PubMedGoogle Scholar
• Zhao H, Xu L, Yang Y, et al. Successful management of decitabine prior to Full-dose idarubicin and cytarabine in the treatment of refractory/recurrent acute myeloid leukemia. Acta Haematol. 2017;137(4):195–200.
   PubMed Web of Science ®Google Scholar
• Zhou H, Zheng C, Zhu X, et al. Decitabine prior to salvaged unrelated cord blood transplantation for refractory or relapsed childhood acute leukemia. Pediatr Transplant. 2016;20(8):1117–1124.
   PubMed Web of Science ®Google Scholar
• Jing Y, Zhu CY, Zhang Q, et al. Clinical efficacy of decitabine combined with modified CAG regimen for relapsed-refractory acute myeloid leukemia with AML1-ETO(+). Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014;22:1245–1250.
   PubMedGoogle Scholar
• Jiang X, Wang Z, Ding B, et al. The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients. Oncotarget. 2015;6:33612–33622.
   PubMedGoogle Scholar
• Qin T, Youssef EM, Jelinek J, et al. Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res. 2007;13:4225–4232.
   PubMed Web of Science ®Google Scholar
• Carter BZ, Mak PY, Mak DH, et al. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. J Natl Cancer Inst. 2014;106:djt440.
   PubMedGoogle Scholar
• Li K, Hu C, Mei C, et al. Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target. J Transl Med. 2014;12(167.
   Google Scholar
• He PF, Zhou JD, Yao DM, et al. Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis. Oncotarget. 2017;8(25):41498–41507.
   PubMedGoogle Scholar
• Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood. 2005;106(4):1154–1163.
   PubMed Web of Science ®Google Scholar
• Shipley JL, Butera JN. Acute myelogenous leukemia. Exp Hematol. 2009;37(6):649–658.
   PubMed Web of Science ®Google Scholar
• Laubach J, Rao AV. Current and emerging strategies for the management of acute myeloid leukemia in the elderly. Oncologist. 2008;13(10):1097–1108.
   PubMed Web of Science ®Google Scholar
• Blum W, Garzona R, Klisovica RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 2010;107(16):7473–7478.
   PubMed Web of Science ®Google Scholar
• Melki JR, Clark SJ. DNA methylation changes in leukaemia. Semin Cancer Biol. 2002;12:347–357.
   PubMed Web of Science ®Google Scholar
• Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21:103–107.
   PubMed Web of Science ®Google Scholar
• Phillips CL, Davies SM, McMasters R, et al. Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults. Br J Haematol. 2013;161(3):406–410.
   PubMed Web of Science ®Google Scholar
• Kretzner L, Scuto A, Dino PM, et al. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res. 2011;71:3912–3920.
   PubMed Web of Science ®Google Scholar
• Bhatla T, Wang J, Morrison DJ. Vepigenetic reprogramming reverse the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood. 2012;119:5201–5210.
   PubMed Web of Science ®Google Scholar
• Stenger EO, Turnquist HR, Mapara MY, et al. Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity. Blood. 2012;119:5088–5103.
   PubMed Web of Science ®Google Scholar
• Wang LX, Mei ZY, Zhou JH, et al. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses. PLoS One. 2013;8:e62924.
   PubMed Web of Science ®Google Scholar